Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation

Launched by DANA-FARBER CANCER INSTITUTE · Apr 13, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to help prevent a painful condition called oral mucositis in patients who are receiving a type of cancer treatment known as hematopoietic cell transplantation. Oral mucositis can cause painful sores in the mouth, which can make it hard to eat and drink. In this study, patients who are scheduled for this treatment will receive daily sessions of a therapy called photobiomodulation using a special LED device, which is designed to help keep their mouths healthy during treatment.

To participate in this trial, patients need to be at least 18 years old and planned for a specific type of transplant. They also need to be able to understand the study and agree to participate by signing a consent form. However, some people may not be eligible if they have had certain previous treatments or conditions that could interfere with the study. If a patient takes part, they can expect to use the LED device daily, which is a simple and non-invasive way to help protect their mouth during a challenging time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Planned to undergo myeloablative allogeneic HCT using FluBu4 conditioning and Tac-Mtx GVHD prophylaxis.
• • Age ≥18 years.
• • Ability to understand and the willingness to sign a written informed consent document.
• Exclusion Criteria:
• • Participants who have had treatment with intraoral PBMT within four weeks of admission for HSCT.
• • Participants who have a history of radiation therapy to the head and neck.
• • Participants who have a history of photosensitivity or underlying disease with known photosensitivity.
• • Participants who are planned to receive palifermin for OM prevention.